Eli Lilly, Summit Therapeutics, and Vertex Pharmaceuticals all have important ongoing clinical trials. Shares of these ...

Malvern, Pennsylvania Tuesday, July 22, 2025, 17:00 Hrs [IST] ...

All 20 US trial sites are now open in the XanaMIA phase 2b/3 trial that is studying oral Xanamem® vs. placebo for 36 weeks, ...

Data from the KEYNOTE-B61 trial show tumor shrinkage in different types of kidney cancer, including papillary and chromophobe ...

Phase 1 Data Highlight RE104 Favorable Safety Profile and Short Duration Psychoactive Experience ---- Topline Results from RECONNECT Phase 2 Trial of RE104 in Postpartum Depres ...

ASCO 2025 showcases breakthroughs in sarcoma treatment, emphasizing precision medicine, immunotherapy, and promising new ...

Treatments for bronchiectasis, chronic immune thrombocytopenia, fibromyalgia, Friedreich ataxia, and recurrent respiratory papillomatosis are under review.

During a live event, Bruna Pellini, MD, discussed IO monotherapy as a first-line option for non–small cell lung cancer with ...

Medpace beats Q2 2025 earnings, raises FY guidance, showcasing strong biotech demand. Click here to read an analysis of MEDP ...

A new review urges oncology researchers to treat patient-reported outcomes as core trial endpoints — not just secondary stats ...

Vusolimogene oderparepvec is a genetically modified herpes simplex type 1 virus designed to directly destroy tumors and generate an anti-tumor immune response.

An oral neutrophil modulator appeared safe and demonstrated signals of efficacy in patients with moderate to severe ...